Abstract
Background: Helicobacter pylori infection affects nearly 50% of the world's population, and 1 to 3% of patients infected with H. pylori have a risk of developing gastric cancer. Probiotics can inhibit the proliferation and adhesion of H. pylori. This study aimed to test Lactobacillus plantarum as an adjuvant therapy in treating H. pylori. Methods: Dyspeptic patients (18-74 years) with gastric infection documented and untreated were randomized into two groups: probiotic group (amoxicillin and clarithromycin for one week, esomeprazole for three weeks and Lactobacillus plantarum 5 x 108 CFU for four weeks) and placebo group (amoxicillin, clarithromycin, and esomeprazole for the same period). Four weeks after therapy, a re-endoscopy was performed. Results: Fifty patients were randomized, and 47 (mean 42.7 SD 14.8 years) concluded the study. The total eradication rate was 78.7% (p = 0.73). Further analyses by age group showed that in patients up to 45 years, the eradication rate in patients who received probiotics was 93.8% against 70.0% in the placebo group (p = 0.046). Conclusion: The results indicate the potential of using probiotics as an adjuvant in eliminating H. pylori, and the greater potential of probiotics use in younger age groups.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
